Key result
EPA-containing interventions fail to improve brachial artery flow-mediated dilation overall.
Why the study?
Eicosapentaenoic acid exerts pleiotropic vascular effects, but whether EPA-containing interventions consistently improve vascular endothelial function remained uncertain.
Does eicosapentaenoic acid (EPA) supplementation improve vascular endothelial function (brachial artery flow-mediated dilation) in subjects with moderate-to-high cardiovascular risk?
Meta-Analysis
Does eicosapentaenoic acid (EPA) supplementation improve vascular endothelial function (brachial artery flow-mediated dilation) in subjects with moderate-to-high cardiovascular risk?
Overall, EPA-containing interventions did not significantly improve brachial artery flow-mediated dilation in moderate-to-high cardiovascular risk subjects, though very low-certainty post-hoc findings suggest purified EPA or durations >12 weeks may provide benefit.
Answers are grounded in this paper and cite their sources.
Does not support prescribing EPA solely to improve endothelial function; leaves open whether longer duration or pure EPA formulations confer meaningful vascular protection.
BACKGROUND: Endothelial dysfunction is an early and mechanistically pivotal step in atherogenesis and an independent predictor of adverse cardiovascular outcomes. Eicosapentaenoic acid (EPA) exerts pleiotropic vascular effects, including modulation of nitric oxide bioavailability, attenuation of oxidative stress, and suppression of pro-inflammatory signaling. Whether EPA-containing interventions consistently improve vascular endothelial function remains uncertain. OBJECTIVES: To systematically review the evidence on the effects of EPA-containing interventions on vascular endothelial function, and to quantify the effect on brachial artery flow-mediated dilation (FMD) through meta-analysis, exploring EPA dose, treatment duration and formulation as potential effect modifiers in post hoc analyses. METHODS: Systematic review and meta-analysis following PRISMA guidelines. Three databases (PubMed, Embase, Scopus) were searched from inception to August 2025, restricted to English-language articles. Twenty-four publications were included in the qualitative synthesis, encompassing assessments of FMD, reactive hyperaemia index, and plethysmographic measures of forearm blood flow. Nine studies providing extractable brachial artery FMD data contributed to the quantitative meta-analysis, analysed using a random-effects model with restricted maximum likelihood estimation. Risk of bias was assessed with the Jadad scale, the Cochrane RoB 2 and the ROBINS-I tools, and the certainty of evidence with GRADE. In exploratory post hoc analyses, formal tests did not support effect modification by EPA dose (>1000 vs ≤1000 mg/day; p = 0.088), whereas treatment duration (>12 vs ≤12 weeks; p = 0.021) and formulation (EPA alone vs EPA + DHA; p = 0.012) modified the effect; however, these subgroups rested on three studies sharing population, dose and design. Excluding crossover trials yielded a statistically significant pooled improvement (MD 0.75%, 95% CI 0.09 to 1.41). No study was at low risk of bias, publication bias could not be reliably assessed, and the certainty of evidence was very low. CONCLUSIONS: EPA-containing interventions produce heterogeneous effects on vascular endothelial function across a range of assessment methods. In the meta-analysis of brachial artery FMD, EPA-containing interventions did not significantly improve endothelial function. Post hoc exploratory sub-analyses suggest a potential role of dose and duration of the treatment, with significant improvements emerging for doses above 1000 mg/day and treatments lasting longer than 12 weeks; however, the small number of studies limited the formal comparison between subgroups. Adequately powered, placebo-controlled trials of purified EPA assessing FMD therefore are warranted. PROSPERO REGISTRATION NUMBER: CRD420251112613.
No takes yet. Share an insight, caveat, or question.
Tirandi et al. (2026) conducted a meta-analysis in Endothelial dysfunction in moderate-to-high cardiovascular risk. Eicosapentaenoic acid (EPA)-containing interventions was evaluated on Brachial artery flow-mediated dilation (FMD). EPA-containing interventions did not improve brachial artery FMD overall, though excluding crossover trials showed a significant benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: